Both the companies offer services in regulatory affairs, Phase I-IV clinical trial management, and clinical trial site management in China.
As part of the acquisition, MedKey/Jiecheng will increase WuXi’s customer base and will focus on clinical services needed by customers for Chinese regulatory filings and market access.
WuXi chairman and CEO Ge Li said its acquisition of Medkey/Jiecheng continues their strategy to build an integrated platform of R&D services that will allow anyone and any company to discover and develop drugs more efficiently and cost effectively for patients.